Infliximab (review) and adalimumab for the treatment of Crohn's disease
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta187
Important information about this guidance
Includes a review of NICE technology appraisal guidance 40
This guidance replaces 'NICE technology appraisal guidance 40' issued in April 2002.
The review and re-appraisal of infliximab for the treatment of severe active or active fistulising Crohn's disease has resulted in a change in the guidance. Specifically, infliximab should now be given as a planned course of treatment until treatment failure (including the need for surgery) or for 12 months, whichever is shorter. Treatment should then only be continued if there is clear evidence of ongoing active disease. Adalimumab is now also recommended as another treatment option for people with severe active Crohn's disease
This guidance was developed using the NICE multiple technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.jsp